<Record>
<Term>Volociximab</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Monoclonal Antibody</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Biological Agent/Monoclonal Antibody/Volociximab</ClassificationPath>
<BroaderTerm>Volociximab</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Biological Agent</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Monoclonal Antibody</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>M200</Synonym>
<Synonym>Volociximab</Synonym>
<Synonym>anti-a5-beta1 Integrin</Synonym>
<Description>A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05)</Description>
<Source>NCI Thesaurus</Source>
</Record>
